Literature DB >> 16429131

The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1.

Karuppiah Muthumani1, Andrew Y Choo, Wei-Xing Zong, Muniswamy Madesh, Daniel S Hwang, Arumugam Premkumar, Khanh P Thieu, Joann Emmanuel, Sanjeev Kumar, Craig B Thompson, David B Weiner.   

Abstract

The Vpr protein of HIV-1 functions as a vital accessory gene by regulating various cellular functions, including cell differentiation, apoptosis, nuclear factor of kappaB (NF-kappaB) suppression and cell-cycle arrest of the host cell. Several reports have indicated that Vpr complexes with the glucocorticoid receptor (GR), but it remains unclear whether the GR pathway is required for Vpr to function. Here, we report that Vpr uses the GR pathway as a recruitment vehicle for the NF-kappaB co-activating protein, poly(ADP-ribose) polymerase-1 (PARP-1). The GR interaction with Vpr is both necessary and sufficient to facilitate this interaction by potentiating the formation of a Vpr-GR-PARP-1 complex. The recruitment of PARP-1 by the Vpr-GR complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-kappaB. The association of GR with PARP-1 is not observed with steroid (glucocorticoid) treatment, indicating that the GR association with PARP-1 is a gain of function that is solely attributed to HIV-1 Vpr. These data provide important insights into Vpr biology and its role in HIV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429131      PMCID: PMC3142937          DOI: 10.1038/ncb1352

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  34 in total

1.  Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5.

Authors:  W Doppler; M Windegger; C Soratroi; J Tomasi; J Lechner; S Rusconi; A C Cato; T Almlöf; J Liden; S Okret; J A Gustafsson ; H Richard-Foy; D B Starr; H Klocker; D Edwards; S Geymayer
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.

Authors:  G Arad; R Levy; D Hillman; R Kaempfer
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

3.  Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome.

Authors:  B E Sawaya; K Khalili; J Gordon; R Taube; S Amini
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

4.  HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro.

Authors:  Karuppiah Muthumani; Daniel S Hwang; Andrew Y Choo; Shanmugam Mayilvahanan; Nathanael S Dayes; Khanh P Thieu; David B Weiner
Journal:  Int Immunol       Date:  2004-12-20       Impact factor: 4.823

5.  HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo.

Authors:  Karuppiah Muthumani; Andrew Y Choo; Daniel S Hwang; Nathanael S Dayes; Michael Chattergoon; Shanmugam Mayilvahanan; Khanh P Thieu; Peter T Buckley; Joann Emmanuel; Arumugam Premkumar; David B Weiner
Journal:  Mol Ther       Date:  2005-07-11       Impact factor: 11.454

6.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 7.  Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism.

Authors:  K Muthumani; A Y Choo; A Premkumar; D S Hwang; K P Thieu; B M Desai; D B Weiner
Journal:  Cell Death Differ       Date:  2005-08       Impact factor: 15.828

8.  HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell.

Authors:  R Geleziunas; W Xu; K Takeda; H Ichijo; W C Greene
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

9.  Poly(ADP-ribose) polymerase-1 is a negative regulator of HIV-1 transcription through competitive binding to TAR RNA with Tat.positive transcription elongation factor b (p-TEFb) complex.

Authors:  Marianne Parent; Tetsu M C Yung; Ann Rancourt; Erick L Y Ho; Stéphane Vispé; Fumihiko Suzuki-Matsuda; Aki Uehara; Tadashi Wada; Hiroshi Handa; Masahiko S Satoh
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

10.  Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2.

Authors:  E Jacotot; K F Ferri; C El Hamel; C Brenner; S Druillennec; J Hoebeke; P Rustin; D Métivier; C Lenoir; M Geuskens; H L Vieira; M Loeffler; A S Belzacq; J P Briand; N Zamzami; L Edelman; Z H Xie; J C Reed; B P Roques; G Kroemer
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  35 in total

Review 1.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

2.  HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.

Authors:  Karuppiah Muthumani; Devon J Shedlock; Daniel K Choo; Paolo Fagone; Omkar U Kawalekar; Jonathan Goodman; Chaoran B Bian; Aarti A Ramanathan; Parikh Atman; Pablo Tebas; Michael A Chattergoon; Andrew Y Choo; David B Weiner
Journal:  J Immunol       Date:  2011-08-19       Impact factor: 5.422

3.  Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.

Authors:  Fei Xu; Yong Sun; Shan-Zhong Yang; Tong Zhou; Nirag Jhala; Jay McDonald; Yabing Chen
Journal:  Int J Cancer       Date:  2019-01-24       Impact factor: 7.396

Review 4.  Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

Authors:  Paul O Hassa; Sandra S Haenni; Michael Elser; Michael O Hottiger
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

5.  Inhibition of NF-κB activity by HIV-1 Vpr is dependent on Vpr binding protein.

Authors:  Michael Kogan; Satish Deshmane; Bassel E Sawaya; Edward J Gracely; Kamel Khalili; Jay Rappaport
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

6.  Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.

Authors:  Karuppiah Muthumani; Katthikbabu M Lankaraman; Dominick J Laddy; Senthil G Sundaram; Christopher W Chung; Eric Sako; Ling Wu; Amir Khan; Niranjan Sardesai; Joseph J Kim; Paluru Vijayachari; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

7.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.

Authors:  Yong Xiao; Gang Chen; Jonathan Richard; Nicole Rougeau; Hongshan Li; Nabil G Seidah; Eric A Cohen
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

8.  Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism.

Authors:  Karuppiah Muthumani; Andrew Y Choo; Devon J Shedlock; Dominick J Laddy; Senthil G Sundaram; Lauren Hirao; Ling Wu; Khanh P Thieu; Christopher W Chung; Karthikbabu M Lankaraman; Pablo Tebas; Guido Silvestri; David B Weiner
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

9.  Genome-wide innate immune responses in HIV-1-infected macrophages are preserved despite attenuation of the NF-kappa B activation pathway.

Authors:  Mahdad Noursadeghi; Jhen Tsang; Robert F Miller; Sarah Straschewski; Paul Kellam; Benjamin M Chain; David R Katz
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

10.  Crystal structures of the X-domains of a Group-1 and a Group-3 coronavirus reveal that ADP-ribose-binding may not be a conserved property.

Authors:  Yvonne Piotrowski; Guido Hansen; A Linda Boomaars-van der Zanden; Eric J Snijder; Alexander E Gorbalenya; Rolf Hilgenfeld
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.